Supplemental Figure 3 from Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma

Post-treatment multi-parametric MR-PET imaging measurements and responses for each oral dose of GDC-0084. Post-treatment measurements of A) contrast enhancing tumor volume, B) median 18F-FDG uptake relative to white matter, C) median ADC, D) median FA, E) median Ktrans, F) median vp¬, and G) median rCBV and change in measurements of H) contrast enhancing tumor volume, I) median 18F-FDG uptake relative to white matter, J) median ADC, K) median FA, L) median Ktrans, M) median vp¬, and N) median rCBV for dose levels of 2, 4, 8, 15, 20, 30, 45, and 65mg.